Endovascular Robotics Market Size, Share, Trends, and Industry Analysis - Global Forecast to 2036 | Market to Reach USD 2.23 Billion as Single-Use Systems, AI, and Telerobotics Drive 24% CAGR
Dublin, Nov. 16, 2026 (GLOBE NEWSWIRE) -- "Endovascular Robotics Market Size, Share, and Industry Analysis - Global Forecast to 2036" has been added to ResearchAndMarkets.com's offering.
The global endovascular robotics market was valued at USD 0.21 billion in 2025 and is estimated to reach USD 0.26 billion in 2026. Revenue is projected to increase to USD 2.23 billion by 2036, representing a CAGR of 24.0% during the 2026-2036 forecast period. The report examines clinical evidence, procedure volumes, epidemiology, robotics and navigation technologies, regulation, reimbursement, occupational safety, competitive activity, and the endovascular robotics value chain.
Market coverage includes electromechanical catheter & guidewire robots, magnetic navigation systems, robotic steerable catheters, and AI-guided navigation technologies. It also evaluates robotic systems, single-use robots & disposables, software, and services across peripheral vascular, coronary, neurovascular, cardiac electrophysiology, structural heart, and interventional oncology applications. General surgical robots, robotic bronchoscopy platforms, and separately sold imaging systems are excluded.
Market Growth Drivers and Challenges
Occupational safety remains a major growth driver for the endovascular robotics market. Interventional cardiologists, radiologists, and neurointerventionalists face prolonged exposure to X-ray radiation and orthopedic strain associated with heavy protective equipment. Robotic platforms allow physicians to operate from protected consoles, supporting radiation reduction, workforce retention, and improved working conditions in catheterization laboratories.
Rising procedure volumes provide an additional catalyst. More than 200 million people worldwide live with peripheral artery disease, while approximately 12 million people experience a stroke annually, according to the World Stroke Organization. Mechanical thrombectomy has become standard care for large-vessel stroke, and aging populations are increasing demand for coronary, peripheral, electrophysiology, and structural heart interventions.
The sector has entered a new development phase following earlier commercialization challenges. Siemens Healthineers ended sales of the Corindus CorPath GRX for vascular procedures in 2023, while Hansen Medical's Magellan system did not achieve broad adoption before the company was acquired by Auris Health in 2016. However, renewed innovation is improving market prospects. On 8 September 2025, Microbot Medical's LIBERTY Endovascular Robotic System received U.S. FDA clearance as the first remotely operated, single-use robot for peripheral endovascular procedures. Its pivotal study reported 100% navigation success to target, no device-related adverse events, and a 92% relative reduction in physician radiation exposure.
Adoption barriers include capital costs, service contracts, limited reimbursement, device compatibility restrictions, reduced tactile feedback, and the need for further clinical evidence. Hospitals also require proof of patient benefits beyond occupational radiation reduction. Regulatory requirements, workflow integration, remote network reliability, and competition from lower-cost radiation protection technologies may further affect adoption.
High-Growth Market Opportunities
Remote and telerobotic stroke intervention represents one of the most significant opportunities. Stroke thrombectomy is time-critical, but neurointerventional specialists remain concentrated in major medical centers. Developers including Sentante, XCath, and Nanoflex Robotics are advancing platforms intended to expand access to specialist care. Additional opportunities are emerging in outpatient peripheral interventions, cardiac electrophysiology, structural heart procedures, AI-assisted navigation, autonomous guidance, magnetic steering, and microrobotics.
Single-use systems and per-procedure pricing are expected to reshape market economics by reducing dependence on large capital budgets. These models are particularly relevant to ambulatory surgery centers & office-based labs, where peripheral vascular procedures are increasingly performed. Compatibility with established catheters and guidewires may also accelerate adoption by limiting disruption to existing clinical workflows.
Segment Outlook
Magnetic navigation systems are expected to account for the largest technology share in 2026, supported by their established use in cardiac electrophysiology and Stereotaxis' clinical presence since its first FDA clearance in 2003. Electromechanical catheter & guidewire robots are projected to record the highest CAGR, driven by single-use platforms and new systems designed for coronary, peripheral, and neurovascular procedures.
Robotic systems are expected to remain the largest product category in 2026 because of the value of installed consoles and magnetic navigation platforms. Single-use robots & disposables are forecast to expand at the fastest rate as per-procedure models improve access for outpatient facilities. Software & services will gain strategic importance as manufacturers add AI navigation, imaging integration, and remote operating capabilities.
Cardiac electrophysiology is expected to lead the application segment in 2026, reflecting the established role of magnetic navigation in ablation procedures and growing atrial fibrillation volumes. Peripheral vascular applications are projected to achieve the highest CAGR, supported by approximately 2.5 million annual U.S. peripheral procedures and the introduction of FDA-cleared single-use robotics. Neurovascular intervention remains a key long-term opportunity because of the potential for remote stroke thrombectomy.
Hospitals are expected to retain the largest end-user share due to their concentration of complex procedures, imaging infrastructure, and capital resources. Ambulatory surgery centers & office-based labs are forecast to grow most rapidly as peripheral procedures move into outpatient settings and capital-free robotic models become available.
Regional Market Analysis
North America is expected to lead the global endovascular robotics market in 2026, supported by high procedure volumes, early medical robotics adoption, and the presence of major developers. The U.S. is the initial market for LIBERTY, which began a limited rollout in November 2025 ahead of a planned full launch in April 2026.
Europe represents a significant market and includes developers such as Robocath in France, Nanoflex Robotics in Switzerland, and Sentante in Lithuania. Regional occupational radiation requirements have also increased attention to clinician protection. Asia-Pacific is projected to register the highest CAGR through 2036, driven by aging populations, expanding catheterization laboratory capacity, large cardiovascular procedure volumes, and strong domestic robotics industries. China performs more than one million percutaneous coronary interventions annually and supports a growing group of vascular robotics developers.
Latin America offers opportunities as Brazil, Mexico, Argentina, and Colombia expand cardiovascular and stroke programs. In the Middle East & Africa, investment in advanced cardiac and neurovascular centers, combined with a high diabetes burden, is expected to support long-term demand.
Competitive Landscape
Competition centers on clinical evidence, regulatory clearance, device compatibility, procedure range, radiation reduction, workflow integration, cost structure, and remote capability. Companies are pursuing new indications, single-use and per-procedure business models, AI-assisted navigation, catheter manufacturer partnerships, regional distribution agreements, and telerobotic functionality.
Key companies profiled include Stereotaxis, Inc. (U.S.), Microbot Medical Inc. (U.S./Israel), Robocath (France), MicroPort Scientific Corporation (China), Siemens Healthineers AG (Corindus) (Germany), Johnson & Johnson MedTech (U.S.), Nanoflex Robotics AG (Switzerland), XCath, Inc. (U.S.), Sentante (Lithuania), and Capstan Medical (U.S.).
The report provides market size estimates and forecasts through 2036, identifies high-growth technologies and applications, assesses regulatory and reimbursement barriers, and benchmarks leading market participants. It supports product development, commercialization, partnership, regulatory planning, and investment decisions across the global endovascular robotics market.
For more information about this report visit https://www.researchandmarkets.com/r/atlief
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

